1. Home
  2. DPRO vs BCTX Comparison

DPRO vs BCTX Comparison

Compare DPRO & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DPRO
  • BCTX
  • Stock Information
  • Founded
  • DPRO 1998
  • BCTX 2014
  • Country
  • DPRO Canada
  • BCTX Canada
  • Employees
  • DPRO N/A
  • BCTX N/A
  • Industry
  • DPRO Aerospace
  • BCTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DPRO Industrials
  • BCTX Health Care
  • Exchange
  • DPRO Nasdaq
  • BCTX Nasdaq
  • Market Cap
  • DPRO 17.3M
  • BCTX 17.5M
  • IPO Year
  • DPRO N/A
  • BCTX N/A
  • Fundamental
  • Price
  • DPRO $2.80
  • BCTX $4.42
  • Analyst Decision
  • DPRO Strong Buy
  • BCTX Strong Buy
  • Analyst Count
  • DPRO 2
  • BCTX 1
  • Target Price
  • DPRO $7.00
  • BCTX $32.00
  • AVG Volume (30 Days)
  • DPRO 130.9K
  • BCTX 965.1K
  • Earning Date
  • DPRO 03-26-2025
  • BCTX 03-17-2025
  • Dividend Yield
  • DPRO N/A
  • BCTX N/A
  • EPS Growth
  • DPRO N/A
  • BCTX N/A
  • EPS
  • DPRO N/A
  • BCTX N/A
  • Revenue
  • DPRO $4,340,793.00
  • BCTX N/A
  • Revenue This Year
  • DPRO $14.33
  • BCTX N/A
  • Revenue Next Year
  • DPRO $115.93
  • BCTX N/A
  • P/E Ratio
  • DPRO N/A
  • BCTX N/A
  • Revenue Growth
  • DPRO N/A
  • BCTX N/A
  • 52 Week Low
  • DPRO $1.55
  • BCTX $0.35
  • 52 Week High
  • DPRO $9.13
  • BCTX $7.87
  • Technical
  • Relative Strength Index (RSI)
  • DPRO 37.04
  • BCTX 61.01
  • Support Level
  • DPRO $3.09
  • BCTX $3.33
  • Resistance Level
  • DPRO $3.34
  • BCTX $5.40
  • Average True Range (ATR)
  • DPRO 0.26
  • BCTX 0.73
  • MACD
  • DPRO -0.02
  • BCTX -0.00
  • Stochastic Oscillator
  • DPRO 2.80
  • BCTX 24.01

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Share on Social Networks: